Year: 2007
Type: editorial
Abstract: The dawn of this century is witness to a paradigm of new treatment strategies for patients with colorectal cancer offering renewed hope for thousands of individuals. Hope is characteristi-cally accompanied by the challenge of potentiating newly acquired gains. Advances should indeed form the construct of the next path toward additional change. In this issue of the Journal of Clinical Oncology, the National Surgical Adjuvant Breast and Bowel Project (NSABP) reports the results from study C-07, demonstrating the 3- and 4-year disease-free-survival (DFS) advantage for stage II and III colon cancer patients who received oxaliplatin combined with weekly bolus fluorouracil (FU) and leucovorin (FLOX) compared with those treated with the weekly bolus FU and leucovorin schedule known as the Roswell Park regimen, the control arm of previous studies.1 These results clearly redefine the superiority of an oxaliplatin-
Source: Journal of Clinical Oncology
Author: Al B. Benson
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2170437811